GLUT-1 content and interaction with stomatin in red blood cells from species without vitamin C biosynthesis and their relevance for diabetes mellitus type 1 by Frey, Tabea Caroline
GLUT-1 content and interaction with
stomatin in red blood cells from species
without vitamin C biosynthesis and their
relevance for diabetes mellitus type 1
Dissertation zur Erlangung eines Doktorgrades der
Naturwissenschaften ( Dr. rer. nat. )
Fakultät Naturwissenschaften
Universität Hohenheim
Institut für biologische Chemie und
Ernährungswissenschaften
vorgelegt von
Tabea Caroline Frey
aus Freiburg im Breisgau
2016
Dekan: Prof. Dr. Heinz Breer
Erstgutachter: Prof. Dr. Hans Konrad Biesalski
Zweitgutachter: Prof. Dr. Jan Frank
Eingereicht am: 22.04.2016
Mündliche Prüfung: 28.07.2016
Die vorliegende Arbeit wurde am 27.06.2016 von der Fakultät
Naturwissenschaften der Universität Hohenheim als 'Dissertation zur
Erlangung des Doktorgrades der Naturwissenschaften' angenommen.
Abstract
Ascorbic acid is commonly known as vitamin C. By deﬁnition, vitamins, with
the exception of vitamin D, are substances which can not be synthesized but are
essential for the organism. In this light vitamin C is special.
It is hypothesized that millions of years ago some species, like primates, guinea
pigs and fruit bats, lost the ability to synthesize ascorbate from glucose due to
an inactivation of an enzyme called L-gulono-γ-lactone oxidase. Since then, these
species have been dependent on dietary intake of this micronutrient. Ascorbate is
not only the most eﬃcient watersoluble antioxidant, but also an important cofactor
in neuro-transmitter or collagen biosynthesis. An inadequate intake of this vitamin
leads to scurvy.
In 2008, a French researcher documented that all species that lost the ability to
synthesize ascorbic acid express a diﬀerent facilitative glucose transporter isoform
(GLUT) in their erythrocytes. The expressed GLUT-1 transports not only glucose
but also dehydroascorbate which is the oxidized form of vitamin C.
Was that diﬀerent GLUT expression the keystone event for the evolutionary success
of these species?
To examine the questions regarding the evolutionary beneﬁt of this transporter
expression, the kinetics of ascorbate and dehydroascorbate transport into erythro-
cytes from four diﬀerent species were evaluated. Further recycling and disposal of
the transported vitamin as well as a possible accumulation were observed.
The results demonstrate that there are three diﬀerent transport types of dehy-
droascorbate. One which does not transport the vitamin at all, one whose transport
of dehydroascorbate competes with glucose and one which absorbs dehydroascorbate
completely independent of the extracellular glucose concentration.
After absorption, vitamin C is not recycled and is not disposed back into the
extracellular ﬂuid. Additionally, it is not stored in the cell until the erythrocyte
undergoes apoptosis. The evolutionary beneﬁt is found in an electron transfer
across the erythrocyte membrane from intracellular ascorbate to the extracellular,
oxidized form of vitamin C. In an energetic light, this recycling of extracellular
Vitamin C is more eﬃcient than the de novo synthesis of the micronutrient.
Therefore, the erythrocyte acts not as a reservoir for Vitamin C storage, but as a
reservoir for electron storage to prevent degradation and loss of dehydroascorbate
in times of high oxidative stress. This electron reservoir becomes more important
in diseases with high levels of oxidative stress.
A metabolic disorder, which is frequently described to be accompanied by high
levels of oxidative stress and lowered vitamin C levels in plasma and cells, is diabetes
mellitus. The decreased plasma concentrations do not result from a smaller dietary
intake. Probably, the uptake of dehydroascorbate into erythrocytes, and, therefore,
the extracellular ascorbate recycling is disordered.
Investigations of the distribution of GLUT-1 in diﬀerent erythrocyte membrane
subdomains showed that the regulation of this transporter is altered in subjects
with diabetes mellitus type 1 compared to healthy controls. In vitro no diﬀerences
in dehydroascorbate transport rate could be observed but signiﬁcantly decreased
intra-erythrocyte vitamin C concentrations were detected in vivo.
In conclusion, the altered regulation of GLUT-1 in the erythrocyte membrane in the
case of diabetes can aﬀect vitamin C recycling in plasma. A decreased ascorbate
pool in the cells leads to a decreased recycling capacity, and, therefore, to a lower
antioxidant defense outside the cell. Due to that knowledge, the recommended
dietary intake of vitamin C in the case of diabetes mellitus must be reconsidered to
prevent further complications.
Zusammenfassung
Ascorbinsäure ist allgemein bekannt unter dem Begriﬀ Vitamin C. Per Deﬁnition
sind Vitamine, mit der Ausnahme von Vitamin D, Substanzen, die ein Organismus
nicht selbst synthetisieren kann, aber die für sein Überleben essentiell sind. In
diesem Fall ist Vitamin C etwas Besonderes.
Vor vielen Millionen Jahren verloren einige Arten von Lebenwesen, wie Primaten,
Meerschweinchen und Flughunde, die Fähigkeit Ascorbinsäure aus Glukose zu
bilden. Auslöser hierfür war eine genetische Mutation, die zu einem inaktiven
Enzym namens L-Gulono-γ-Lacton Oxidase führte. Von diesem Zeitpunkt an waren
genannte Arten auf die Zufuhr dieses Mikronährstoﬀes mit der Nahrung angewiesen.
Ascorbat ist nicht nur ein äußerst eﬀektives wasserlößliches Antioxidanz, sondern
auch ein wichtiger Kofaktor bei der Herstellung von Neurotransmittern und
Kollagen. Eine unzureichende Zufuhr führt zu der typischen Mangelerscheinung
von Vitamin C, genannt Skorbut.
Im Jahr 2008 konnte eine französische Forscherin zeigen, dass alle Arten, die
die Fähigkeit zur Vitamin C Synthese verloren hatten, einen anderen Glukose-
transporter (GLUT) in ihren Erythrozyten besaßen. Dieser Transporter, GLUT-1,
transportiert nicht nur Glukose, sondern auch die oxidierte Form von Vitamin C,
Dehydroascorbat.
War diese veränderte Expression einer Transporter-Isoform das Schlüsselereignis
für das Überleben dieser Arten?
Um die Frage des evolutionären Vorteils dieser GLUT-1 Expression zu erörtern,
wurde die Aufnahme von Ascorbat und Dehydroascorbat in Erythrozyten von vier
verschiedenen Arten analysiert. Weiterführend wurden ein intrazelluläres Recycling
mit anschließender Disposition sowie eine mögliche lebenslange Akkumulation von
Vitamin C untersucht.
Die Ergebnisse konnten drei verschiedene Isoformen des Glukosetransporters
identiﬁzieren. Eine, die kein Vitamin C, sondern nur Glukose transportiert, in
der zweiten ist eine Konkurrenz zwischen Dehydroascorbat und Glukose deutlich
ersichtlich und in der dritten Form ist die Dehydroascorbat-Aufnahme nicht von
Glukose beeinﬂussbar.
Im Anschluss an die Aufnahme wird Dehydroascorbat zwar reduziert, aber nicht
wieder in die extrazelluläre Flüssigkeit entsandt. Ebenso wird es nicht bis zum
Zelltod angereichert.
Der evolutionäre Vorteil der Dehydroascorbat-Aufnahme besteht in einem Elek-
tronenﬂuss über die erythrozytäre Membran von intrazellulärem Ascorbat zu den
extrazellulär lokalisierten oxidierten Formen des Vitamins. Dieses Recycling von
extrazellulärem Vitamin C ist energetisch eﬃzienter als die de novo Synthese des
Vitamins. Der Erythrozyt ist daher kein Speicher für Vitamin C, sondern ein
Reservoir für Elektronen, die in Zeiten erhöhten oxidativen Stresses extrazelluläres
Vitamin C durch Reduktion vor der Selbstzerstörung und der Ausscheidung
schützen. Dieses Reservoir für Elektronen gewinnt in Erkrankungen an Relevanz,
in denen vermehrt oxidativer Stress entsteht.
Diabetes mellitus ist eine Erkrankung des Zuckerstoﬀwechsels, die oft mit erhöh-
tem oxiativen Stress und verminderten Vitamin C-Spiegeln in Plasma und Zellen
einhergeht. Diese verminderten Konzentrationen resultieren hierbei nicht von ei-
ner inadäquaten Zufuhr des Mikronährstoﬀes mit der Nahrung. Möglicherweise ist
die Aufnahme von Dehydroascorbat in die Erythrozyten gestört, so dass weniger
Elektronen für das Recycling von extrazellulärem Vitamin C bereitgestellt werden
können.
Untersuchungen einer Verteilung von GLUT-1 zwischen verschiedenen Membranab-
schnitten im Erythrozyt zeigten, dass die Regulation des Transporters bei Patienten
mit Diabetes verändert ist. In vitro resultierten keine Unterschiede im Transportver-
halten von dieser veränderten Verteilung des Transporters. In vivo wurden jedoch
signiﬁkant verminderte Vitamin C Konzentrationen in Erythrozyten von Personen
mit Diabetes beobachtet.
Schlussendlich beeinﬂussen die gefunden Unterschiede in der GLUT-1 Distribution
das Vitamin C Recycling im Plasma. Ein verminderter Gehalt an Vitamin C in den
Erythrozyten führt zu einer schlechteren Reduktion von extratellulärem Vitamin C
und damit zu einem geringeren antioxidativen Schutz. Mit diesen neuen Erkennt-
nissen ist es nötig die Zufuhrempfehlungen für Patienten mit Diabetes noch einmal
zu überdenken, um Ihnen einen optimalen Schutz vor oxidativem Stress und damit
verbundenen Folgeerkrankungen zu gewährleisten.
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Chapter 1
Introduction
1.1 Vitamin C and evolution
Ascorbic acid is commonly known as vitamin C. By deﬁnition, vitamins, with the
exception of vitamin D, are substances that cannot be synthesized by, but are
essential to the organism. In this light, vitamin C is special. All living species
have the genome to synthesize ascorbic acid from glucose. The last step of this
synthesis is the oxidation from L-gulono lactone to L-ascorbic acid by the enzyme
L-gulono-γ-lactone oxidase (GLO) [1]. Some species including men, monkeys, fruit
bats and guinea pigs lost this ability millions of years ago due to mutations leading
to the inactivation of this enzyme [2, 3]. Henceforward, these species have been
dependent on dietary vitamin C intake. Because of missing storage systems for
ascorbate (AA), the plasma and extracellular concentrations of the antioxidant are
seasonally ﬂuctuating [4].
Ascorbic acid acts as co-factor in copper-dependent monooxygenases and iron-
dependent dioxygenases involved in dopamine and collagene synthesis, respectively
[5]. Furthermore, ascorbate is the most important antioxidant in plasma [6]. In
the cell, it acts as a primary antioxidant and interacts directly with radical species
[7]. In the plasma membrane, it can reduce the α -tocopheroxyl radical to α
-tocopherole and protect the fatty acids of the lipid bilayer from peroxidation by
chain reaction [8].
With loss of ascorbate biosynthesis, certain species apperar at ﬁrst glance to have
been handicaped compared to synthesizing species. The deﬁciency of ascorbate
leads to scurvy [2, 9]. In the course of evolution, only the ﬁttest species succeeds.
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Thus, a still unsolved question is how the lack of vitamin C biosynthesis has been
compensated for and how these GLO-lacking species could compete against the
synthesizing ones.
In 2008, Montel-Hagen and coworkers detected a diﬀerent glucose transporter
isoform in red blood cell (RBC) membranes in species which lost the AA biosynthe-
sis [10]. The expressed facilitative glucose transporter isoform 1 (GLUT-1) instead
of GLUT-4 also transports dehydroascorbate (DHA) which is the oxidized form of
vitamin C (see ﬁgure 1.1) [11, 1, 12]. Further, that transporter connects to a mem-
brane protein called stomatin. The interaction of these two molecules leads to the
preference of DHA transport over glucose [11]. This GLUT-1 dependend transport
seems to be the only way RBCs can absorb vitamin C [13, 14]. RBCs express no
active sodium dependent vitamin C transporter (SVCT), and are, therefore, not
able to take up AA [15]. Even when the detailed mechanisms of DHA absorption
and metabolism are not fully discovered, this GLUT-1 expression in RBCs is sup-
posed to be the key to the explanation, why species unable to synthesize vitamin C
survived in the course of evolution.
1.2 Facilitative glucose transporter isoform 1, stom-
atin and transport of dehydroascorbate and glu-
cose
GLUT-1 is one of 14 known glucose transporter isoforms [16, 17]. It was ﬁrst isolated
and puriﬁed from erythrocyte membranes, and, therefore, it is often described as the
erythrocyte glucose transporter [18]. With 5% of the total protein content, GLUT-1
has the highest occurence in RBC membranes [16]. The transporter is constitutively
present in plasma membrane and therefore responsible for the basal glucose uptake
[19, 20]. But not all GLUT-1 molecules in the plasma membrane are constitutively
active. There are suggestions that a pool of transporter molecules is `masked` and
is only activated by changes in the covalent molecule structure [21]. Further, Ku-
mar and colleagues demonstrated that a targeting of GLUT-1 molecules into lipid
rafts, also called detergent resistant membranes (DRM), activates the transporter
and favors the uptake of glucose [20].
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Figure 1.1: Oxidation products of ascorbate
DRM are `free-ﬂoating` subdomains in the plasma membrane that are rich in choles-
terol and sphingolipids and resistant to weak detergents like Triton X [22]. They
seem to have regulative structures. Proteins which are located in these membrane
microdomains are frequently modiﬁed by palmitoylation and phosphorylisation [20].
These modiﬁcation of transporter proteins can aﬀect their aﬃnity for substrates.
For example, a phosphorylisation of GLUT-1 on serine-226 or S-490 increases the
transport activity of glucose [23, 24]. Further typical proteins which are found in
DRM like stomatin [25] and ﬂotillins [26] favor oligomerization of proteins which
also aﬀects the localization and activity of transporter molecules [27, 28].
Thus, an interaction of GLUT-1 and stomatin can only take place in these regula-
tory membrane regions. An overexpression of stomatin in cells results in decreased
glucose transport into these cells [29, 30]. In summary, GLUT-1 molecules located
in the plasma membrane are inactive and become activated by being modiﬁed and
translocated into DRM [31]. When GLUT-1 connects to stomatin, this transporter
prefers DHA as substrate [11].
1.3 Vitamin C metabolism and red blood cells
Oxidized forms of ascorbate like ascorbyl free radical (AfR) or DHA are gener-
ated by enzyme dependent oxidation or by autooxidation of this vitamin. The
antioxidant can transfer up to two electrons to radical substances like reactive
oxygen species (ROS) (ﬁgure 1.1 [1]). The two electron oxidized form of vitamin
C, DHA, is unstable and degrades to 2,3-diketo-1-gulonic acid with a half life of 5
to 7 minutes [32, 33, 34]. This hydrolysis of DHA is irreversible and results in the
urinary excretion of the former vitamin. In vitro, this degradation can be inhibited
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by addition of reduced glutathione (GSH) [35], but the addition of GSH to plasma
can not recycle AA in vivo [36].
In plasma, DHA concentrations of <2µM can be found [37, 32]. The missing
accumulation of DHA in plasma results from the described degradation and from
the fast absorption of the GLUT-1 substrate into RBCs [38]. After transport
into erythrocytes, the vitamin is immediately reduced back to ascorbate [36].
The erythrocytes have two possible mechanisms to regenerate that vitamin. The
required electrons can be derived from reduced nicotinamide adenine dinucleotide
phosphate (NADPH+H+) in an enzyme dependent reduction or from reduced
glutathione (GSH) in enzyme dependent or spontaneous reduction. The GSH
dependent reaction is 10-fold more eﬀective in vitro, but the GSH depletion of RBCs
does not result in complete termination of AA recycling [39, 40]. The produced
ascorbate either cannot or can only very slowly cross the erythrocyte membrane
and is trapped in the cell [41, 42] .
There are two hypothesis regarding the beneﬁt of this DHA absorption by
RBCs:
First, it is possible, that this intra-erythrocyte accumulation of vitamin C to
concentrations higher than in the extracellular medium is a mechanism of vitamin
C storage [43]. The absorbed DHA is reduced back to ascorbate which can not
leave the cell, and the vitamin is not released back to extracellular ﬂuids until the
cell undergoes apoptosis.
On the other hand it was supposed, that the RBC can transfer electrons from
intracellular molecules to extracellular substances [44]. Thus, the accumulation of
AA results in an increased pool of electrons which could increase the antioxidative
defense in blood [45].
1.4 Vitamin C and diabetes
Decreased vitamin C plasma concentrations [46, 47, 48, 49] as well as lowered intra-
cellular ascorbate concentrations [50, 51] were frequently observed in patients with
diabetes mellitus. These observed diﬀerences were not caused by a reduced dietary
intake of the vitamin compared to the healthy population.
In context of the described DHA uptake into RBCs, these lowered vitamin C concen-
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trations could be explained by an increased DHA production in diabetic metabolism.
In general, the level of oxidative stress is increased in diabetes compared to healthy
controls [52, 53]. Greater oxidative stress results in more production of DHA
molecules which irreversibly degrade, if they are not absorbed by cells like RBCs.
The transport of DHA can be aﬀected by either the rate of intracellular reduction or
by a modiﬁed or disturbed interaction of GLUT-1 and stomatin or by a combination
of both.
There is evidence that the glucose-6-phosphate dehydrogenase (G6PDH) activity
is decreased in diabetics [54, 55]. G6PDH catalyzes the oxidation of glucose-6-
phosphate to 6-phosphogulonolactone which is the entry of the hexose monophos-
phate pathway (HMP). The metabolism of less glucose molecules via the HMP
results in a decreased number of NADPH+H+. GSH is NADPH+H+ dependently
reduced by the glutathione reductase (GR) which also shows a reduced activity in
case of diabetes and hyperglycemia [55]. GSH can directly or enzyme dependently
reduce DHA as described above.
Alterations in the protein interaction of GLUT-1 and stomatin could inhibit the
preference for DHA uptake leading to a competition between glucose and DHA for
GLUT-1 as is observed in RBCs as well as in other cell types [56, 57, 58]. The
protein interaction can only take place in DRMs. Possibly, GLUT-1 is modiﬁed in
diabetes, and, therefore, unable to translocate into these membrane domains [22].
To summarize, a decreased DHA absorption by RBCs in diabetic subjects can aﬀect
the intra- and extracellular recycling of ascorbate, resulting in a decreased DHA/AA
and AfR/AA ratio [59, 47], and, therefore, increased degradation and loss of vitamin
C.
1.5 Objective of this research
It was reported in 2008 that all species, which lost the ability to synthesize vitamin
C, express another glucose transporter in their RBCs. This GLUT-1 expression
was seen as the keystone event for evolutionary success of these species. This work
should give more information about the context of GLUT-1 expression and the loss
of vitamin C synthesis. Further, analyses of DHA transport into RBCs from diﬀer-
ent species should reﬂect that the ability to accumulate DHA leads to evolutionary
success of the 'ﬁttest' phenotype.
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If this hypothesis will prove correct, the beneﬁt of this vitamin C accumulation
should be identiﬁed. So far, there are contradictory hypotheses for this vitamin C
accumulation: RBCs could be seen as a possibility for vitamin C storage, or as a
recycling station to protect the water soluble vitamin from degradation.
Further, this thesis will focus on GLUT-1 regulation in diabetes mellitus. Frequently
lowered vitamin C plasma levels have been described previously, but no explanation
for this phenomenon could be proved correct. This work provides a new hypoth-
esis to explain the lowered vitamin C plasma concentrations observed in diabetes
mellitus by focusing on the regulation of GLUT-1 in RBC membranes. If there are
alterations in GLUT-1 regulation and/or in interaction with stomatin, the vitamin
C metabolism could be disturbed.
In summary, this work should lead to a better understanding of vitamin C
metabolism in non-synthesizing species.
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Chapter 2
Materials and Methods
On the following pages, all applied methods are described in detail. The exact
composition and preparation of all self-made buﬀers can be found in the appendix.
2.1 Ethical applications
All blood sample collections were approved by an ethical committee.
Table 2.1: Ethic committees and approvals
species ethical committee application number
human Medizinische Fakultät, Univer-
sitätsklinikum Tübingen
674/2013BO2
rat Landesuntersuchungsamt Rhein-
landpfalz
23177-07/G12-1-023
Pig blood was received from animals for slaughter (StaufenFleisch®, Göppingen,
Germany). Therefore, no ethical application was necessary. Wistar rats were pur-
chased from Charles River (Sulzfeld, Germany), ODS rats from Clea (Japan). Rat
blood was received from animals, that were excluded from research approaches of
the department for physiology and pathophysiology at the University of Mainz. The
rats were older than 6 weeks with a weight of >220g.
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2.1.1 Study population
Healthy subjects were recruited at University of Hohenheim. Diabetic patients were
screened and included in the doctor's oﬃce of Dr. med. Anne Schreiber (Stuttgart,
Germany). Included were only male persons in the age of 18 - 40 years, type 1
diabetics were only included with a glyco-hemoglobin A (HbA1c) <10%. Excluding
criteria were high blood pressure (systole >140mm Hg and diastole >90mm Hg),
excess weight (body mass index (BMI) >35 kg/m2), increased serum cholesterol
(>220 mg/dl), smoking and the intake of vitamin C supplements. Detailed data are
found in the appendix (table 5.1 and ﬁgure 5.1 on page 57)
2.2 Sampling and treatment of whole blood
2.2.1 Blood sampling
Whole blood from human volunteers was sustained by puncture of the vena
cubitalis, after cleaning the skin with a disinfectant. Whole blood was drawn into
EDTA-coated S-Monovettes® (Sarstedt, Nümbrecht, Germany) and immediately
mixed by swinging to prevent coagulation.
Pig blood was received from the institute of farm animal science (University of
Hohenheim, Germany). Blood was received from animals, which had to be culled
by a butcher. Blood was also drawn in EDTA-coated S-Monovettes® and treated
like described before.
The Wistar and ODS-rats were anesthetized with Florene® 100% (AbbVie, Lud-
wigshafen, Germany) before they were killed by neck rupture. The blood was drawn
directly from the heart into an ethylenediaminetetraacetic acid (EDTA)-coated
syringe and was transferred within the next two minutes into a S-Monovette® to
prevent coagulation.
For plasma vitamin C analysis 1ml of the blood sample was centrifuged for ten
minutes at 1000 xg and room temperature. All centrifugation procedures with rat
blood were made at 1500 xg instead of 1000 xg. Plasma was stabilized by adding
the same volume of 5% perchloric acid (PCA). All samples were stored at -80◦C
till high performance liquid chromatography (HPLC) analysis.
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2.2.2 Isolating and puriﬁcation of erythrocytes
For all analysis of intracellular erythrocyte AA, the cells must be free of white
blood cells and plasma. To remove plasma and buﬀy coat completely an Easycoll®
density layer was used (Merck Millipore, Berlin, Germany). Therefore Easycoll®
and phosphate buﬀered saline (PBS) were adjusted to a density of 1.081g/ml. 2ml
of this solution were transferred on the bottom of a centrifuge tube and carefully
overlayed with 8 to 10 ml of whole blood. After centrifugation for 10 minutes at
1000 xg at room temperature without brake the erythrocytes moved through the
Easycoll®-layer to the bottom of the tube, overlayed by Easycoll® solution following
the white buﬀy coat and plasma-PBS on top. Everything except the red blood cells
was rejected, the erythrocytes were washed once with the same volume of PBS to
remove the Easycoll® solution completely.
Rat blood was centrifuged without a density layer. The buﬀy coat and the upper
red cell layer were rejected carefully to remove all white blood cells. To ensure that
all white blood cells are removed, this washing procedure was repeated twice.
Pure erythrocytes were used for analysis of the distribution of membrane proteins
in DRM as well as for the uptake kinetics of vitamin C, co-culture assays with
HMEC-1 cells and for age-dependent AA assays. For DRM analysis the packed pure
erythrocytes were stored at -80◦C after incubation in buﬀer, containing diﬀerent
amounts of glucose, AA and ascorbate oxidase (Ao) (table 2.2.2). Cell culture
experiments, uptake kinetics and age-dependent AA assays were started immediately
after puriﬁcation of the cells.
2.3 Uptake of AA and DHA into erythrocytes
Puriﬁed erythrocytes were adjusted with PBS, containing diﬀerent amounts of glu-
cose, 100µM AA with or without Ao, to a hematocrit of 25%. For uptake kinetics
after appropriate incubation time, a sample (400µl) was taken out of the cell-buﬀer
mixture. The sample was centrifuged (1000 xg, RT, 70 seconds, brake 7), the su-
pernatant was removed and the cells were washed once with the same volume of
pure ice cold PBS. After removing the supernatant, the packed cells (100µl) were
lysed in ﬁve volumes of ice cold ultra pure Water (500µl), vortexed and immediately
stabilized with the same volume of 5% PCA (600µl). All samples were stored at
-80◦C till HPLC analysis.
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Table 2.2: Final composition of incubation buﬀer for analysis of erythrocyte DRM
proteins
Glucose (mM) AA (µM) Ao (mUnits/ml)
3 0 0
3 100 0
3 100 5
5 0 0
5 100 0
5 100 5
25 0 0
25 100 0
25 100 5
Cell Counting and hemoglobin (Hb) determination
To verify an equal hematocrit value in every incubating cell-buﬀer suspension, the
cell number of 400µl sample (i.e. 100µl packed cells) was determined. Therefore one
sample (400µl) of each suspension was taken and washed as described above. The
packed erythrocytes were suspended in 10ml of Casyton® and mixed by swinging
upside down for 20 times. 100µl of this cell solution were transferred into 10 ml
of fresh Casyton® and carefully mixed by swinging. This step was repeated a
second time, the ﬁnal dilution was 1:106. The measurement was done with the cell
counter system Casy® using a 60µm capillary. The cell number was calculated as
mean of three measurements, in each measurement the number of cells in 200µl
cell suspension was counted. Only cells, with an diameter lager than 3.8µm were
considered (human). Erythrocytes from animals were smaller, the limit was adjusted
to 3.3µm for rat and 3.6µm for pig erythrocytes.
Another method to adjust the intracellular AA to the cell number was to deter-
mine the Hb content of one aliquot out of each approach. Therefore the samples were
treated as described but not stabilized with 5% PCA. The lysed cells were trans-
ferred to a 96-well plate (Sarstedt, NÃ¼mbrecht, Germany) and the absorbance at
546nm was measured as mean of three measurements.
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2.4 AA eux measurements
RBCs were puriﬁed and incubated in PBS with 5mM glc and either 100µM AA or
100µM AA and 5mU Ao per ml solution for 3 hours. Afterwards cells were washed
twice with 4ml PBS and resuspended in PBS with 5mM glucose and 200µM reduced
glutathione for stabilization of released AA by the cells. The hematocrit was ad-
justed to 25% during the 'loading' of the cells and during the eux measurements.
For measurement of the AA release every 30 minutes a sample of 400µl were trans-
ferred into a micro vial, centrifuged (1000 xg, 70 seconds, room temperature (RT))
and the supernatant was stabilized with the same amount of 5% PCA. The samples
were stored at -80◦C till HPLC analysis.
2.5 Erythrocyte separation by age
Whole blood from volunteers was withdrawn like described before. 1ml of blood
was centrifuged for 3 min at 1500 xg at RT, plasma was stabilized with the same
volume of 5% PCA for HPLC-analyses and stored at -80◦C. The buﬀy coat was
removed and the erythrocytes were washed once with Casyton®. 300µl of the cells
were transferred to a 15ml Falcon and mixed with 10ml Casyton for measurement
of whole erythrocyte intracellular AA content.
Up to three ml of whole EDTA-blood from healthy and diabetic volunteers was
carefully transferred on top of an density gradient of three Easycoll® layers: 2ml of
a solution with a density of 1.081g/ml was under layed by 2ml of each, an 1.092g/ml
and an 1.098g/ml Easycoll® solution. The gradient was centrifuged for 30 minutes
at 1000 xg and RT without brake. Afterward 4 cell layers could be seen: on top of
the 1.081g/ml solution under the yellow plasma was a white ring: the buﬀy coat.
Between 1.081g/ml and 1.092g/ml was a red ring of 5-10% of all RBCs: the youngest
erythrocytes. Between the 1.092g/ml and 1.098g/ml layers was the biggest amount
of Cells: the middle aged erythrocytes. On the bottom of the tube (under the
1,098g/ml solution) the oldest erythrocytes accumulated (ﬁgure 2.5).
Plasma and buﬀy coat were rejected, young RBCs were transferred into a 15ml
Falcon tube as well as the oldest cells. The cells were washed once with Casyton®.
After removal of the supernatant the amount of packed cells was estimated and the
cells were resuspended in an adequate volume of Casyton® so the cell number per ml
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Figure 2.1: Age dependent separation of RBCs using a density layer gradient
was approximate equal in all (young, old, and unseperated) cell solutions. 5 aliquots
to 400µl of each cell fraction were made. After centrifugation for 3 minutes at 1500
xg and RT the supernatant was removed and four aliquots were lysed with 250µl
icecold ultra pure water and immediately stabilized with 270µl 5% PCAand stored
at -80◦C till HPLC-analysis. The last aliquot was lysed in 250µl ultrapure water
and the Hb content was determined in three replicates at 546nm. The measured
intracellular AA content was adjusted to the absorbance, so all samples could be
compared to each other.
2.6 Detergent resistant membrane protein analysis
2.6.1 Isolation of erythrocyte DRM by a sucrose gradient
Puriﬁed erythrocytes were incubated in PBS with diﬀerent amounts of glucose or
glucose and AA respectively AA and Ao to produce DHA (table 2.2.2).
The frozen pure erythrocytes were thawed on ice. First the membranes ('ghosts')
were isolated. 200µl packed cells were lysed in 15 volumes of ice cold 5mM
Sørensenbuﬀer pH 8.0 containing 1.5mM Na3VO4 (phosphatase inhibitor) and
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protease inhibitor cocktail (sigma-aldrich, Munich, Germany). The lysate was
centrifuged at 20000 xg and 4◦C for 20min to collect the membranes at the
bottom of the ultracentrifuge tubes. The pellet containing the membranes and
few hemoglobin molecules was precise homogenized in 5mM Sørensen buﬀer and
centrifuged again to remove hemoglobin residues.
The pure membranes were incubated on ice for 30 minutes in PBS containing 0.5%
Triton X 100, 1.5mM Na3VO4 and protease inhibitor (PBS-TX) to disrupted the
non detergent resistant membranes. At beginning and end of the incubation time
the solution was homogenized by using a 0.9mm (beginning) or a 0.6mm (end)
needle to suspend the cell membranes to mechanical and physical stress. 1.5ml of
this membrane homogenate were mixed with 1.5ml PBS containing 80% sucrose
(table 2.3) on the bottom of an ultracentrifuge tube. This cell solution was carefully
overlayed with 6ml PBS containing 30% sucrose and 3 ml PBS containing 5%
sucrose. The gradient was centrifuged for 17 hours at 260000 xg at 4◦C without
brake.
From the top to bottom fractions of 1ml were collected and transferred into mirco
tubes. In fraction 3, 4 and 5 the DRM could be seen as a white ring. The residual
membrane stayed in the three fractions on the tube bottom (10, 11 and 12).
Fractions 1 and 2 as well as 6 to 9 were droped.
Proteins were precipitated by 208µl 72% trichloroacetic acid (TCA) per ml
sample. The samples were incubated at 4◦C on a shaker for two hours followed
by centrifugation (15000 xg, 5 min 4◦C). The supernatant was removed and the
protein pellet solved in 800µl ice cold (-20◦C) acetone. All samples were frozen over
night at -20◦C. The next day the pellets were mechanically broken with a spatula,
centrifuged and resolved in fresh acetone. This washing procedure was repeated till
the pellet was crumbly. The acetone was removed with a pipette and the samples
were kept on ice under the ﬂow for 2 hours till acetone residues were evaporated.
The three DRM- and the three non DRM fractions were solved in 60µl (DRM)
and 80µl (non DRM) colorless SDS-buﬀer and stored at -20◦C till protein deter-
mination and sodium dodecylsulfate polyacrylamide gel eletrophoresis (SDS PAGE).
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Table 2.3: Preparation of sucrose solutions for density gradient
solution sucrose PBS Na3VO4 protease inhibitor
80% 12g 15ml 150µl 7,5µl
30% 12g 40ml 400µl 20µl
5% 1g 20ml 200µl 10µl
2.6.2 SDS PAGE, Westernblot and immuno chemical protein
detection
The protein determination was operated with the DC protein assay kit (Bio-Rad,
Hercules, United States).
All samples were diluted to a concentration of 0.75µg protein/15µl. To 15µl Sample
5µl of 4-fold concentrated SDS buﬀer was added to get a ﬁnal concentration of
β-mercaptho ethanol of 5% and bromphenole blue of 0,03% . For all SDS PAGEs
a 10% separating gel and a 5% loading gel were used. The PAGE was running
for about one hour at 100V. The proteins were blotted on a polyvinylidene
diﬂuoride (PVDF)-membrane at 41mA per gel with Trans-Blot® Turbo transfer
system (Bio-Rad, Hercules, United States).
All Antibodies were solved in TBST (tris buﬀered saline with 0,05% Tween 20) with
5% bovine serum albumin (CarlRoth AG, Karlsruhe, Germany). The incubating
times of each solution is shown in table 2.4. After incubation with primary and
secondary antibodies, the membrane was washed three times for 5 minutes with
TBST to remove all residues of antibody solution. The detection of the protein
bands was operated with the ChemiDoc XRS system by using the application
'chemi high sens'. To take a picture of the molecular weight marker the application
'epi white' was choosen. Both pictures were merged to check if the protein bands
have the right molecular weight.
Densitometric evaluation of Westernblots
For statistical analysis the eﬀects, seen of Westernblots, were brought into metric
data. Therefore the blot pictures were analyzed with imageJ 1.48v (National in-
stitute of Health, United States). The blackness of the bands (pixel density) was
estimated in metric data for analysis.
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Table 2.4: Antibody dilutions and incubation times
target protein description manufactorer dilution incubation time
anti-stomatin rabbit polyclonal,
epitop: H-45
santacruz 1:750 overnight, 4◦C
anti-GLUT-1 rabbit polyclonal,
c-terminal
Merck 1:750 1 hour, RT
anti-rabbit goat polyclonal,
peroxidase conju-
gated
Merck 1:2000 1 hour, RT
Problems of this calculation was that only bands of the same blot could be compared
to each other. Further the blackness of bands was dependent to the handling, e.g.
the volume of the chemiluminescent substrate that was distributed on each blot. So
on each blot all to compared samples were applicated and in the statistical analysis
an eﬀect of each blot was modeled.
2.7 High performance liquid chromatography anal-
ysis
HPLC analysis was done by using a reversed phase C18-AQ column (Dr. Maisch
GmbH, Ammerbuch, Germany) with a diameter of 5µm. For mobile phase a 3.7mM
NaH2PO4*H2O solution was adjusted to pH 3.0 with meta-phosphoric acid. The ﬂow
rate during measurement was 1.0ml/min. A coulometric cell (Analytic cell 5011A
from esa) was used, the sensivity of the detector (range) was 20µA, the potential
was -300mV in the ﬁrst cell, and 300mV in the second. For detection a Coulochem
II detector from esa was used in combination with an autosampler and software
system from Shimadzu Corporation (Duisburg, Germany).
All samples stored at -80◦C were thawed at 4◦C and immediately centrifuged (15000
xg, 5 min, 4◦C) when thawed. All samples were kept on ice to reduce depriva-
tion of vitamin C by temperature. Plasma samples were measured twice, once
by adding 10µl pure water and a second time by adding 10µl of a 750mM Tris(2-
carboxyethyl)phosphine (TCEP). TCEP is a reducing agent that reduces the ox-
idized forms of vitamin C (monohydroascorbate and DHA) to AA. In cell lysates
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and standards always TCEP was added.
Standards were prepared fresh each time before measurement. The concentrations
were 0, 0.5, 1, 2.5, 5, 10, 25, 50, 75, 100µM. Injections volume was 20µl for standards
and samples. Analyses and Integration of the area under the curve (AUC) was cal-
culated with LabSolutions© software 5.54 SP2 (Shimadzu Corporation, Duisburg,
Germany).
2.8 Cell culture
HMEC-1 cells were received from Center for Disease Control and Prevention
(CDC, Atlanta, United States). The cells were cultured in MCDB 1312 medium
(Biochrom, Berlin, Germany) with 1g/L glucose, 10% FCS (Biochrom, Berlin, Ger-
many), trace elements (Biochrom, Berlin, Germany), 1% Penicilin- Streptomycin
solution (100U/ml ﬁnal concentration (Biochrom, Berlin, Germany)), Putrescin
(Biochrom, Berlin, Germany), 1µg/ml Hydrocortison (sigma-aldrich, Munich, Ger-
many), 10ng/ml EGF (Biochrom, Berlin, Germany) and 1ng/ml VEGF-α (Invitro-
gen, Carlsbad, United States), with 100µM AA once a week.
Cells were seeded with a concentration of 5*105 cells / 75cm2 ﬂask. The cells were
splitted once a week. Therefore the medium was removed and the cell layer was
washed twice with 5ml PBS-. After removing the buﬀer completely 1.5ml of a
0.05% EDTA - 0.02% Trypsin solution was given on the bottom of the ﬂask and
were equally distributed by swinging the ﬂask from side to side. Then the cells
were incubated at 37◦C with 5% CO2 for 4 minutes to break oﬀ the cell adhesion
molecules. The cells were chipped oﬀ the ﬂask by knocking on the bottom. When
the cells were detached 10ml of medium was added to stop the enzyme activity. The
cell solution was transferred into a 50ml falcon and the cells were isolated by pipet-
ting them 15 times up and down with a glass pipette. 100µl of this homogenate were
diluted in 10ml of Casyton® and the cell number per ml solution was determinate
with the cell counting system CASY®. Cells were then seeded with a concentration
of 5*105 cells per T75 ﬂask or 10cm dish or 2*105 cells per 60mm dish. Medium was
changed each day after splitting the cells.
2special cell culture medium for human microvascular endothelial cell lines
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2.8.1 Uptake kinetics of ascorbate and dehydroascorbate into
HMEC-1
For each time point of the kinetic one 10cm dish was seeded ﬁve or six days before
as described above. Medium was removed and the cells were washed once with 4ml
PBS-. Fresh complete medium was prepared with 100µM AA for AA uptake, or
with 5mU/ml Ao for DHA uptake. 8ml of the appropriate medium was transferred
to each dish. For uptake kinetics of DHA AA was given to each dish immediately
before the time was started, otherwise the enzyme began to metabolize AA to early.
All dishes except the start value were stored in the incubator (37◦C with 5%CO2).
The start value was lysed directly after the PBS- was removed. Therefore 300µl
5% PCA was dripped on the cell layer and the cells were scratched oﬀ with a spat-
ula, transferred into an microtube and homogenated by passing through a 0.9mm
needle for 20 times. The cell samples were stored at -80◦C till HPLC analysis and
deoxyribonucleic acid (DNA) determination. The incubated cells were washed twice
with PBS- before the cells were lysed and scratched oﬀ like described before.
2.8.2 DNA determination assay
The DNA content of each cell sample was determined to relate the measured in-
tracellular AA concentration to the cell number which was grown on a dish. Cell
lysates were thawed on ice or in the fridge (4◦C). 200µl homogenized cell lysate
were taken out oﬀ each aliquot and centrifuged at 21000 xg for 5min at 4◦C. The
supernatant was transferred into an HPLC vial as described before. The pellet
(proteins and DNA) was washed twice with icecold pure ethanol to remove PCA
residues. Herring sperm was used for standards with concentrations of 0, 1, 2, 5, 10,
20 and 30µg DNA. All samples and standards were dried over night in a speed-vac
or freeze drier. To the dried pellets were 400µl solution A' were added (16%PCA
with 0,04%acetaldehyde), to the standards 200µl solution A'. Afterwards 640µl of
solution B (4% Diphenylamine in pure acetic acid) was given to all samples (320µl
to each standard). The samples were vortexed for 10 seconds and incubated at 37◦C
for about 20 hours.
After centrifugation for 30 seconds at 5000 xg each well was ﬁlled with 200µl sample
or standard solution. The absorbance was measured at 590nm with reference at
750nm.
17
The quantitative determination occurred by the straight calibration line estimated
with the standards.
2.9 Statistical analysis
All data were analyzed with statistic software SAS 9.4 (SAS Institute Inc., Cary,
United States). First all data was tested for Gaussian distribution and homogeneity
of variance. If necessary data were transformed before analysis. Data were analyzed
by adapting a mixed model including all qualitative and quantitative parameters;
persons were deﬁned as random parameter. Degrees of freedom were adjusted
after Kenward Rodger. For all analyses a p-value of <0.05 was considered to be
signiﬁcant and is markes with a ∗.
For each experiment a new model was adjusted to the data. For a better under-
standing of modeling the SAS code of uptake kinetic analysis is explained.
Figure 2.2: SAS code for the mixed model adapted for analysis of uptake kinetics in
diﬀerent species
The data showed no homogeneity of variances so all data were transformed by
natural logarithm (TAA). In the class statement all qualitative variables were de-
ﬁned: 'group' for the species, 'number' for each individual, 'glc' for glucose level,
'treat' for the treatment, i.e. addition of Ao and 't' as qualitative time for calcu-
lation of lsmeans (ﬁgure 2.2). The model is composed of the ﬁx eﬀects group, glc
and treat with all possible interactions. Further 'initasc' is taken into the model as
covariable, caused by the observation, that species with a higher RBC AA to the
beginning, took up more than RBCs with lower AA levels. Further the statement
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'group*glc*treat*time' models a linear gradient to test of the uptake rates are diﬀer-
ent from each other and signiﬁcant. The statement '\random t\sub=group*number'
models an random eﬀect for each individuum in each group in consequence if the
assumption, that all samples derived from one individual are more similar to each
other than samples from diﬀerent individuals. For the same reason the '\repeated
t\sub= group*number*glc*treat' statement was modeled with the diﬀerence that in
this statement the repeated measurements over time in each treatment are focused.
For the visualization of the data all results calculated by least square means
(LSMEANS) statement were transformed back. The standard errors could not be
transformed back (statistically not acceptable), so all graphics with re-transformed
data show no standard errors. For the original graphics of the transformed date
with standard errors have a look in the appendix.
2.10 Evaluation of AA stability in PBS and
turnover to DHA by ascorbate oxidase
Before start of the uptake kinetic measurements the stability of AA in PBS and
the turnover from L-AA to L-DHA (the substrate for GLUT-1) by ascorbate
oxidase (Ao) was controlled to guarantee physiologic concentrations. Figure 2.3
shows no changes in AA concentration in PBS with diﬀerent glucose concentrations
over a period of 3 hours (ﬁlled bars). Ao oxidizes AA into DHA which is not stable
in PBS and thus the measured concentration continuously decreases (pattern bars).
Per minute and ml 5nMol AA are converted to DHA at pH 5.6 (manufactorer's
information). Figure 2.3 shows a decrease in AA concentration of 0.5µM per minute
(90µM in 180 minutes) what corresponds to a conversion of 0.5nMol per minute and
ml. The diﬀerence between the manufactorer's speciﬁcations and the real measured
AA conversion can be explained by the diﬀerence of pH. The incubation media (pH
7.3 to 7.4) diﬀer a lot from the enzyme's optimum pH of 5.6, so the activity of the
Ao is smaller and less AA is oxidized.
In summary, the concentration of generated DHA equates to the physiological DHA
concentration in plasma which is <2µM [37, 32].
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Figure 2.3: Stability of AA in PBS with and without Ao over a period of 3 hours. The
initial AA content in PBS did not diﬀer from that after 3 hours. When incubated with Ao
the AA content signiﬁcantly decreases over time (data denoted with ∗).
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Chapter 3
Results and Discussion
The following chapter contains two thematic sections. First part focuses on the
transport of AA and DHA into red blood cells (RBCs) and the scientiﬁc relevance
of this uptake for species able and unable to synthesize vitamin C. The second part is
about the molecular regulation of DHA transport. The distribution of the membrane
proteins GLUT-1 and stomatin was evaluated to identify possible diﬀerences in
RBC membrane composition in subjects with diabetes mellitus type 1 and healthy
controls.
3.1 Physiologic relevance of dehydroascorbate up-
take into human red blood cells
The objective of this research was to identify the evolutionary and scientiﬁc role of
DHA uptake into RBCs in vitro. First, the uptake of AA and DHA into RBCs of
diﬀerent species was observed. The purpose was to examine whether only species
which can not synthesize AA express GLUT-1 in their RBC membrane, and, there-
fore, can transport DHA. Further, a possible competition between DHA and glucose
uptake by GLUT-1 was examined.
3.1.1 Ascorbate and dehydroascorbate uptake into red blood
cells of diﬀerent species
Erythrocytes obtained from human volunteers only absorbed the oxidized form of
vitamin C (ﬁgure 3.1, page 22). In this context a signiﬁcant constant transport of
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Figure 3.1: Accumulation of AA (continous lines) and DHA (broken lines) in human
RBCs over a period of 3 hours (n=6). ∗ denote signiﬁcant diﬀerences (p<0.05) in vitamin
C treatment (AA compared to AA+AO) at the same glucose concentration and time. The
transformed data with errorbars is shown in the appendix, ﬁg. 5.7, page 61.
DHA over a period of 3 hours could be seen as documented before by Vera et al.
[60]. The extracellular glucose concentration did not aﬀect the transport of neither
AA nor DHA.
To make sure that this uptake of DHA is speciﬁc for species which are unable
to synthesize AA the absorption of AA and DHA into RBCs obtained from pigs
who can synthesize vitamin C was evaluated. Pig erythrocytes took up neither AA
nor DHA (ﬁgure 3.2, page 23). Therefore, it seems likely that DHA uptake into
erythrocytes is an exclusive skill of species without AA biosynthesis like supposed
by Montel-Hagen before [11, 10].
To ensure that the expression of GLUT-1 molecules in erythrocyte membrane was
an evolutionary development, and, therefore, was not triggered by modiﬁcations
during erythropoesis which are caused by the lack of AA synthesis, i.e. changes
in intra- and extracellular AA concentrations in bone marrow or other tissues, the
transport of DHA and AA into two rat species, Wistar rats and ODS rats, was
examined.
Wistar rats are a AA synthesizing species like pigs and no transport of DHA into
rat erythrocytes was documented in Spraque Dawley rats before [61]. Further, no
GLUT-1 was detected in rat RBCs [11] (a representative Westernblot is shown
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Figure 3.2: Accumulation of AA (continous lines) and DHA (broken lines) in pig RBCs
over a period of 3 hours (n=4). The transformed data with errorbars is shown in the
appendix, ﬁg. 5.8, page 62.
in the appendix, ﬁg. 5.4, page 60). Surprisingly the Wistar rats signiﬁcantly
absorbed DHA and accumulated the vitamin in their erythrocytes (ﬁgure 3.3,
page 24). The transport was negatively aﬀected by the extracellular glucose
concentration. That means, there was a competition between glucose and DHA
for the GLUT-transporter in Wistar rat RBCs. These ﬁndings indicate that
Wistar rats have facilitative glucose transporter isoform 3 (GLUT-3) in their RBC
membrane which is the second DHA transporting glucose transporter isoform [12,
62]. Westernblot analysis conﬁrmed this assumption (see ﬁg 5.5 on page 60).
In conclusion, the classiﬁcation of species into those which can synthesize vitamin
C and which lost this ability gives no information about whether DHA is absorbed
by their RBCs. Thus, not all species with AA synthesis express facilitative
glucose transporter isoform 4 (GLUT-4) in RBCs as hypothesized by Montel-Hagen
previously [11, 10], and, therefore, are unable to absorb the oxidized form of vitamin
C.
To identify whether the loss of an active GLO modiﬁes the DHA transport in the
same species, erythrocytes from ODS rats were isolated. ODS rats are the same
species as Wistars, but lost the ability to synthesize AA due to an inactive GLO
[63].
RBCs obtained from ODS rats also absorb DHA (ﬁgure 3.4, page 25). The transport
23
Figure 3.3: Accumulation of AA (continous lines) and DHA (broken lines) in Wistar
RBCs over a period of 3 hours (n=3). ∗ denote signiﬁcant diﬀerences (p<0.05) in vitamin
C treatment (AA compared to AA+AO) at the same glucose concentration and time. ♦
marked data points are signiﬁcantly diﬀerent (p<0.05) compared to 5mM glucose but the
same vitamin C treatment,  marked data is signiﬁcantly diﬀerent (p<0.05) compared to
25mM glucose within the same vitamin C treatment. The transformed data with errorbars
are shown in the appendix, ﬁg. 5.9, page 62.
competes with the extracellular glucose concentration as seen before in Wistar rats,
but the accumulated vitamin C concentration is signiﬁcantly increased in ODS
compared to Wistar rats (ﬁgure 3.5, page 25). Consequently, DHA transport that
is independent of the extracellular glucose concentration, seems to be a human
characteristic and not a universal feature of all species unable to synthesize AA.
These results indicate that RBCs from ODS rats adapted to the lacking AA
biosynthesis, but not in the same way as humans, i.e. primates did. The missing
competition between glucose and DHA seems to be a unique feature and cannot be
universally transferred to all non-vitamin C-synthesizing species.
To identify whether this glucose-concentration-independent DHA transport can
be seen in other human cell types, the uptake of AA and DHA into immortalized
human microvascular endothelial cells (HMEC-1) was examined. Endothelial cells
are in contact with RBCs and can also transport DHA [64]. Surprisingly the DHA
uptake into HMEC-1 competes with the extracellular glucose concentration. In
hyperglycemic (25mM) medium the cells take up signiﬁcantly less DHA than in
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Figure 3.4: Accumulation of AA (continous lines) and DHA (broken lines) in ODS rat
RBCs over a period of 3 hours (n=3). ∗ marked data points show signiﬁcant diﬀerences
(p<0.05) in vitamin C treatment (AA compared to AA+AO) at the same glucose con-
centration. ♦ marked data points are signiﬁcantly diﬀerent (p<0.05) compared to 5mM
glucose and the same vitamin C treatment, marked data is signiﬁcantly diﬀerent (p<0.05)
compared to 25mM glucose within the same vitamin C treatment. The transformed data
with errorbars are shown in the appendix, ﬁg. 5.10, page 63.
Figure 3.5: Comparison of ln-transformed data of DHA accumulation in RBCs which were
obtained from Wistar and ODS rats. ∗ denotes signiﬁcant diﬀerences (p<0.05) between
the rat species at the same time and treatment.
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normoglycemic (5mM) medium (Appendix, ﬁgure 5.3, page 59). This competition
had been described in other human cell lines before [57, 58].
In conclusion, all these results demonstrate that a DHA transport system that is
independent of the extracellular glucose concentration, is a unique characteristic of
human RBCs. Neither human endothelial cells nor erythrocytes of ODS rats trans-
port DHA without competition with the extracellular glucose concentration. But
ODS rats have an increased DHA transport compared to their synthesizing rela-
tives. Therefore, it is possible that the lack of AA biosynthesis can be compensated
by modiﬁcations of the given transport molecules, resulting in an increased DHA
transport rate as observed in ODS rats. But the complete glucose-concentration-
independent absorption of DHA is not only a result of modiﬁcations of transport
molecules. In RBCs from all analyzed species, stomatin was detected (Appendix,
ﬁg. 5.6, page 61). Therefore, stomatin cannot be the keyprotein for DHA transport.
Thus, it may be presumed that the key to DHA transport, which does not compete
with glucose, is the expression of GLUT-1 molecules in human RBCs.
GLUT-3 transports DHA at the same rate as GLUT-1 does, but GLUT-3 can not
translocate into detergent resistant membranes (DRM) [20], and, therefore, GLUT-1
is the only glucose transporter which can interact with stomatin [29, 11]. If this
interaction is the key to glucose-concentration-independent DHA absorption, the
decreased transport into RBCs of ODS rats would be explained.
But still there is no explanation for the competition between glucose and DHA for
transport in HMEC-1. Both cell types contain GLUT-1 and stomatin molecules in
their membranes and DRM (data not shown). The only diﬀerence is that HMEC-
GLUT-1 molecules have a molecular weight of∼55 kDa and RBC-GLUT-1 molecules
show a high variance in their weight (45 kDA to 65 kDa) (ﬁgure 3.6, page 27). These
diﬀerences in molecular weight are caused by modiﬁcations of the protein like N-
glycolysation [31, 23], palmitoylation [20] and phosphorylisation [24] at various sites.
Probably, these post translational modiﬁcations enable the interaction of GLUT-1
with stomatin in RBCs resulting in the missing competition in transport of DHA
with glucose.
But still, the question regarding the beneﬁt of transport and accumulation of
DHA in RBCs remains. Possibly, RBCs act as a kind of AA reservoir which absorbs
DHA, recycles the vitamin [43, 36] and disposes AA molecules into plasma at times
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Figure 3.6: Representative Westernblot of GLUT-1 in human endothelial cells
(HMEC-1, left side) and human RBC (right side).
when the extracellular level are decreasing as postulated by Hornig et al. [42]. A
higher transport rate would lead to more reduced AA in plasma and, therefore, to
a better antioxidative defense.
3.1.2 Ascorbate disposal from human red blood cells
To evaluate whether erythrocytes accumulate and reduce DHA and further release
AA to the extracellular ﬂuids, AA loaded and unloaded erythrocytes were trans-
ferred into medium without AA and the extracellular concentration of the vitamin
was measured during 3 hours. Loaded RBCs released signiﬁcantly more AA than
unloaded cells (ﬁgure 3.7, page 28). The initial intracellular AA concentration had
a signiﬁcant eﬀect on the disposed amount, i.e. the higher the intracellular vitamin
C concentration at start of the measurement the more molecules were disposed of.
But despite a big diﬀerence in concentration of vitamin C from ∼70µM AA inside
the RBC to 0µM outside the cell the release is negligible (about 1.3µM in 3 hours
in loaded and 0.5µM in 3 hours in unloaded cells). A comparable small eux of
vitamin C was documented in RBCs of guinea pigs [42]. So neither men nor guinea
pigs actively disposed of reduced vitamin C into the extracellular ﬂuids.
As there is no active transport of AA out of the cell, DHA transport via GLUT-1
could be a possible explanation for the observed results. Intracellular AA can act
as an electron donor resulting in a low percentage of intracellular DHA. Also,
RBCs are able to transfer electrons across their membrane to reduce extracellular
substances like ferricyanide [45]. Thus a turnover from intracellular AA to DHA
is likely and the produced DHA molecules can cross the membrane via facilitative
diﬀusion by GLUT-1. Thus, the observed disposal of vitamin C is a passive eux
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Figure 3.7: AA concentration in extracellular media where loaded and unloaded RBCs
were incubated in (n=3) corrected to the initial vitamin C concentration. The increase of
extracellular vitamin C is signiﬁcantly higher in the medium with loaded RBCs. Signiﬁcant
diﬀerences (p<0.05) in extracellular vitamin C concentration are denoted by ∗.
of DHA. In conclusion, RBCs do not absorb and recycle DHA for AA disposal to
guarantee a constant amount of reduced vitamin C in plasma.
3.1.3 Ascorbate content of diﬀerent aged red blood cells
RBCs do not release AA into the extracellular ﬂuid by active transport as demon-
strated before but still the question remains why the cells absorb and recycle DHA.
Since RBCs are not able to dispose of AA an accumulation of vitamin C over the
whole lifespan of the cells must occur. The AA pool which is 'stored' in RBCs
will be released into the circulation when the cells undergo apoptosis. This might
explain, why scurvy typically occurs after vitamin C deﬁciency for longer than 10
weeks [65]. That precisely corresponds with the lifetime of erythrocytes [66].
Figure 3.8 on page 29 shows, that old RBCs have signiﬁcantly less intracellular
AA compared to middle aged and young cells. Consequently, RBC are no reservoir
for vitamin C storage for times in which vitamin C is not available in the diet.
The transport of DHA into RBCs diminishes over a period of 16 days in vitro
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Figure 3.8: ln-transformed data of AA concentration in RBCs with diﬀerent ages corrected
to Hb content (n=6). The vitamin C content decreases with age. Signiﬁcant diﬀerences
(p<0.05) are denoted by ∗.
[67]. Possibly, in vivo the transport activity also decreases with the age of the
erythrocytes and less DHA is absorbed. But without a gate to exit the cells, the
intracellular vitamin C concentration must increase despite lower transport activity.
There is no explanation for, where the vitamin goes or how it is used.
What is the beneﬁt of uptake and reduction of this essential substance? And why
is this transport of DHA documented in species which lost the GLO activity like
humans and guinea pigs [42, 61, 56, 11], but not in any synthesizing species?
Possibly, it is not the vitamin's physiological function as a co-factor for several
enzymes or antioxidant that the cells are interested in, but the molecule's chemical
structure. Ascorbic acid can emit two electrons which means, one molecule of
AA can quench two radicals. Further, the oxidized vitamin, i.e. AfR and DHA
molecules, can be regenerated immediately because all enzymes and electron donors
needed for AA recycling are available in RBCs. So, erythrocytes might not be
a reservoir for vitamin C but for electron storage. James May demonstrated,
that RBCs can transport electrons over their membrane to reduce extracellular
molecules [45]. Further, it was shown that erythrocytes reduce extracellular AfR
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molecules by a transfer of electrons from intracellular AA molecules across the
membrane [68] and that RBCs are able to regenerate 35µM AA in blood every 3
minutes [36].
This reduction capacity of RBCs does not decrease immediately after inhibition
of glucose and DHA transport by Cytochalasin B [7] - an GLUT-1 inhibitor [69].
Thus, the electron transfer can be sustained even when the extracellular conditions
change. That might be evidence for the existence of an electron pool inside the
erythrocyte.
This leads to the assumption, that the evolutionary key advantage of the
expression of GLUT-1 instead of GLUT-4 in red blood cell membrane is the
transport of a molecule
a) that is able to 'store' two electrons and increase the antioxidant defense pool of
the organism,
b) that is much smaller than the usual electron donors NADPH+H+ and GSH,
c) that can easily be recycled within the cell,
d) that can not be synthesized by the organism but is needed for many metabolic
steps further and is released back to plasma when the cells undergo apoptosis and
e) that would otherwise be degraded and lost via the kidney.
In times without evolutionary pressure many diﬀerent phenotypes of one species
develop. Regarding the RBCs, there must had been species expressing GLUT-1,
GLUT-3, GLUT-4 and other isoforms in their RBCs under the condition that these
changes in transport molecules had not been a disadvantage of glucose transport.
After the loss of the L-gulono-γ-lactone oxidase (GLO) and the ascorbate
synthesis, the ﬁttest phenotypes succeeded. Figure 3.9 on page 31 shows three
diﬀerent pathways of glucose metabolism in a cell (under the hypothesis, that all
cells have all enzymes and are able to synthesize vitamin C). Anaerobic glycolysis is
the most common pathway where 6 adenosine triposphate (ATP) and no reduction
equivalents are generated.
In the pathway of ascorbate synthesis, 1 glucose molecule is required to undergo
glycolysis to supply the required activation energy (2 ATP). Therefore 3 glucose
molecules are required for a biosynthesis of 2 AA molecules. These 2 AA molecules
can transfer 4 electrons over the membrane and reduce 4 AfR or 2 DHA molecules
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Figure 3.9: Hypotetic possibilities of intracellular glucose metabolism and its relevance
for AA recycling.
in plasma. Considering the loss of 2 NADPH+H+, even one additional glucose
molecule is required to undergo the HMP. Thus, AA synthesis is from an energy
counting perspective not very proﬁtable.
In the hexose monophosphate pathway 3 glucose molecules are converted to 5 ATP
and 6 NADPH+H+. These reduction equivalents can reduce 6 intracellular DHA
molecules to AA resulting in a net transfer of 12 electrons across the membrane.
This enables the extracellular reduction of 12 AfR or 6 DHA molecules under the
energetic loss of 1 ATP.
In an energetic light, the recycling of DHA is more eﬃcient than the de novo synthe-
sis of AA from glucose. Necessary for this recycling is the availability of vitamin C
from the diet. If vitamin C is available, phenotypes expressing GLUT-3 or GLUT-1
are not disadvantaged and can compete with the 'common' phenotype which ex-
presses GLUT-4 [11]. This is due to their increased 'recycling' of AfR or DHA with
their increased intracellular ascorbate pool. After the loss of the GLO, all species
that could absorb DHA into RBCs and regenerate electrons via the HMP to reduce
extracellular DHA and quench ROS may have had an adaptive advantage. Individ-
uals expressing GLUT-4 might not have been able to scavenge all radicals due to the
absence of DHA transport, recycling and electron storage by intracellular vitamin C.
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Interestingly, newborns of all species express GLUT-1 in their RBCs [10]. After
three weeks, GLUT-1 could not be detected in the erythrocyte membrane of dogs,
cows, rats and mice. This neonatal GLUT-1 expression enables the absorption of
DHA and therefore the recycling of extracellular AA by RBCs in the ﬁrst two to
three weeks. In this period, the de novo synthesis of AA is not enabled [70].
The recommended daily allowances (RDA)s of species unable to synthesize vitamin
C are signiﬁcantly lower than the RDAs of species with artiﬁcial knock-out of
AA biosynthesis: Nutrition of knock-out mice and rats must be supplemented
with 200mg - 300mg AA per kg and day [4, 71] to prevent scurvy. In contrast,
guinea pigs need about 2mg AA per kg and day [72] and humans only 1mg - 1.5mg
vitamin C per kg and day [73, 4]. Newborn calves, which express GLUT-1 in their
erythrocytes are in the same range need about 2-2.5 mg per kg and day[70]. The
ODS rat has a maintenance dose of 10mg per kg [72].
The diﬀerences in the RDA of ODS rats compared to humans, guinea pigs and
newborn calves might be due to diﬀerent expressed GLUT transporters. ODS
rats express GLUT-3, as previously stated, so, the higher RDA results from the
competition between DHA and glucose for the transporter (ﬁg. 3.4, page 25). The
transport of DHA via GLUT-1 is completely glucose-concentration-independent,
whereas the absorption by GLUT-3 competes with glucose. Vitamin C plasma
levels increase after dietary intake of fruits, vegetables or root vegetables which
also contain carbohydrates. Thus, both plasma vitamin C and plasma glucose
concentrations rise after dietary intake. A competition of DHA with glucose results
in decreased transport of DHA into RBC due to the concentration diﬀerences
of plasma DHA (<2µM [37, 32]) to plasma glucose (>8.8mM postprandial after
consumption of raw or green leaf vegetables [74, 75]). Under normoglycemic
conditions, the absorption of DHA was more than 3-fold lower in ODS rat RBCs
than in human cells. Postprandial, this eﬀect will be ampliﬁed further resulting in
a 4-fold reduced intra-erythrocyte vitamin C concentrations (see ﬁg. 5.2, page 58).
A lack of competition between DHA and glucose for the transporter favors evolu-
tionary success. Vitamin C intake occurs only in combination with dietary intake
of carbohydrates, i.e. glucose. Therefore, the expression of GLUT-1 facilitated the
absorption of DHA, whereas GLUT-3 did not and GLUT-4 transports no DHA at
all.
The expressed transporter isoform is responsible for the intracellular concentration
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vitamin C, and, therefore, the intra-erythrocyte electron pool. This ability for
electron storage and the transfer of electrons cross over the membrane elucidates
the diﬀerences in the diﬀerent species' RDAs:
ODS rats have a 4-fold increased RDA of vitamin C compared to guinea pigs [72]
(10mg/kg and day compared to about 2.5mg/kg and day). Via the HMP, up to
6-fold more electrons are provided compared to the AA biosynthesis (ﬁg. 3.9, page
31). These regenerated electrons reduce the intracellular vitamin C molecules and
can be disposed of when necessary. A 4-fold increased intra-erythrocyte ascorbate
pool means that 4-fold more electrons can be stored and that in times with high
oxidative stress 4-fold less vitamin is required in diet because of the oxidative
defense dependent on the RBCs. Further, this electron transfer, and, therefore, the
antioxidative defense also works in times when only little glucose is available.
To summarize, the dietary intake of vitamin C can decrease without any complica-
tions as long as the generation and storage of electrons within the RBC works.
The small diﬀerences in the RDA of newborn calves and guinea pigs compared
to humans results from the loss of the urate oxidase (uricase) which metabolizes
uric acid to allatonin in purine metabolism. Uric acid acts as a potent antioxidant
in plasma by scavenging ROS [76] like vitamin C does. Due to the loss of urate
oxidase, uric acid levels in plasma of humans and primates are increased [77]. It is
possible that the loss of urate oxidase further decreases the RDA for vitamin C in
humans due to the antioxidative nature of uric acid.
In conclusion, the expression of GLUT-1 and -3 in RBCs enables the absorption
of DHA and increases the antioxidant defense of blood by recycling of extracellular
oxidized forms of vitamin C. The recycling is energetically more eﬃcient than the de
novo synthesis of AA. Thus, also species with an active GLO might have a beneﬁt,
but no disadvantage by expressing one of these two transporter isoforms and could
compete with other phenotypes that can explain the transport of DHA into rat
RBCs.
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3.2 Diﬀerences in the distribution of the membrane
proteins GLUT-1 and stomatin in detergent re-
sistant membranes of red blood cells from sub-
jects with diabetes mellitus type 1 compared to
healthy controls
In plasma AA is recycled by transfer of electrons across the erythrocyte membrane
[68]. Frequently, decreased plasma vitamin C levels were observed in subjects with
diabetes mellitus [46, 47, 48, 49]. Lower AA concentrations in plasma can be caused
by either a higher production of DHA by oxidative stress and less absorption of
this molecule, or from by a decreased recycling of AfR molecules by RBCs. In both
hypothesis the transport of DHA into the RBC and its intracellular reduction plays
a key role. The absorption of DHA can be aﬀected by either a competition of DHA
with glucose resulting in a smaller transport of DHA in normo- and hyperglycemic
media, or by an altered interaction of GLUT-1 and stomatin which contributes to a
decreased number of active DHA transporter proteins.
3.2.1 Eﬀect of extracellular glucose on the distribution of
GLUT-1 and stomatin in detergent resistant mem-
branes
The eﬀect of extracellular glucose on the GLUT-1 content of DRMs was examined
(ﬁg. 3.10, p. 35). In healthy subjects a signiﬁcant negative correlation between
GLUT-1 and the extracellular glucose concentration was observed (ﬁgure 3.11, page
36). Surprisingly RBCs from diabetic subjects show a signiﬁcant lower GLUT-1
content in DRM than healthy cells do and no eﬀect of extracellular glucose on
GLUT-1 content can be detected.
These ﬁndings are supported by Meena Garg, who recently showed that RBCs
of subjects with clinical type 1 diabetes contain less GLUT-1 molecules [78] in
erythrocyte membrane. The diﬀerences in the absolute GLUT-1 number can explain
the signiﬁcant decreased amount of GLUT-1 molecules in DRM of diabetic subjects.
A smaller total number of GLUT-1 proteins in RBC membrane results in a decreased
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Figure 3.10: Representative Westernblot of GLUT-1 and stomatin in healthy (left 3 lanes)
and diabetic (right 3 lanes) RBCs which were treated with diﬀerent glucose concentrations
(3mM, 5mM and 25mM respectively).
number of transporters which can be shuttled into DRM. But the smaller number of
GLUT-1 molecules does not explain why diabetic cells do not respond to changes of
the extracellular glucose concentrations. That could be ﬁrst evidence for a missing
regulation of GLUT-1 shuttle in diabetes.
In RBCs of healthy controls a transport of GLUT-1 molecules into DRM under
hypoglycemic conditions was documented. These ﬁndings match the observations
made by Anil Kumar, who reported a movement of GLUT-1 molecules into DRM
after glucose deprivation[20]. The translocation of GLUT-1 resulted in an increased
glucose transport activity due to the activation of inactive 'masked' transporters
by shuttle into DRM, probably [21].
Consequently, the movement of GLUT-1 molecules represent a regulatory mecha-
nism to ensure required energy uptake. This matches the observed ﬁndings (ﬁgure
3.11, page 36) of less GLUT-1 molecules in DRM under hyperglycemic conditions
and more GLUT-1 in DRM in a hypoglycemic environment. A higher concentration
of glucose molecules results in an increased chance for one molecule to ﬁnd a
transporter. When less glucose is available in plasma, the cell needs more active
transporters to increase the likelihood for glucose uptake.
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Figure 3.11: Ratio of GLUT-1 to stomatin bands of DRM isolated from RBC after incu-
bation with 3, 5 or 25mM glucose (n=8). Signiﬁcant diﬀerences (p<0.05) between the two
groups are denoted by ∗.
In summary, the number of GLUT-1 molecules in DRM depends on the extracel-
lular glucose concentration. But in diabetic samples no changes of GLUT-1 content
was detected. Possibly, the regulation of glucose uptake into RBCs is disordered
in diabetes. There are observations of an increase membrane microviscosity of dia-
betic RBCs which could possibly complicate GLUT-1 shuttling into DRM [79]. If
RBCs from diabetic subjects can not shuttle their GLUT-1 into DRM, the uptake
of DHA would be altered, too. If there is no shuttle of GLUT-1 into DRM, there
is no possibility to interact with stomatin resulting in a decreased DHA uptake [11]
and recycling [36]. Consequently, more DHA remains in plasma which is degraded
and renaly excreted. Finally, the plasma ascorbate level decrease despite adequate
dietary intake as frequently described [46, 47].
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3.2.2 Eﬀect of extracellular ascorbate on the distribution
of GLUT-1 and stomatin in detergent resistant mem-
branes
After treatment with glucose in combination with AA, the healthy samples showed
small changes in DRM content of GLUT-1 compared to the samples treated with
glucose only (ﬁgure 3.11, page 36). RBCs can not transport the reduced form of
vitamin C [38] (see ﬁgure 3.1, page 22). So there is no need for the cells to shuttle
more GLUT-1 into DRM than is needed for energy homeostasis.
Diabetic RBCs incubated with a combination of glucose and AA showed increased
GLUT-1 movement into DRM compared to treatment with glucose only (glucose:
∼1.5 glucose and AA: >2.2).
Further, the GLUT-1 content signiﬁcantly increased (p<0.0002) with the extracellu-
lar glucose concentration in DRM from diabetic RBCs. At a concentration of 25mM
glucose, diabetic RBCs contained signiﬁcantly more GLUT-1 in DRM than healthy
controls did.
Figure 3.12: Ratio of GLUT-1 to stomatin bands of DRM isolated from RBC after incu-
bation with 3, 5 or 25mM glucose and 100µM AA (n=6). Signiﬁcant diﬀerences (p<0.05)
between the two groups are denoted by ∗.
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Figure 3.13: Ratio of GLUT-1 to stomatin bands of DRM isolated from RBCs after
incubation with 3, 5 or 25mM glucose, 100µM AA and 5mU ascorbate oxidase to generate
phsyiologic concentrations of DHA (n=6). Signiﬁcant diﬀerences (p<0.05) between the
two groups are denoted by ∗.
These results show that diabetic RBCs are able to move GLUT-1 into DRM.
This shuttling is induced by extracellular ascorbate. This highlights the important
role of this vitamin in diabetes mellitus type 1.
3.2.3 Eﬀect of extracellular dehydroascorbate on the distri-
bution of GLUT-1 and stomatin in detergent resistant
membranes
In DRM from healthy controls which were treated with DHA and glucose no
diﬀerences in GLUT-1 content were detected (ﬁgure 3.13, page 38). All treatments
contained the same amount of DHA. A constant content of GLUT-1 demonstrates
that healthy RBCs prefer the uptake of DHA over glucose as was suggested before
by Montel-Hagen [11].
Diabetic RBCs showed the highest amount of GLUT-1 in DRM when incubated
with 25mM glucose and DHA. In ﬁgure 3.12 on page 37, diabetic erythrocytes
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contained the most GLUT-1 proteins when incubated in high glucose PBS and AA.
This leads to the assumption, that diabetic RBCs are stimulated by the combination
of high extracellular glucose concentration and vitamin C to translocate GLUT-1
into DRM. Hyperglycemic conditions favor the formation of ROS [80] resulting in
a higher level of oxidative stress which is generally increased in individuals with
diabetes mellitus [52, 53]. The movement of GLUT-1 might be an compensatory
regulation to protect the vitamin from extracellular degradation.
For the recycling of the oxidized form of vitamin C, reduced glutathione (GSH) is
required (see ﬁg. 3.9 on page 31). For the recycling of an increased amount of DHA,
the RBC also needs more glucose to generate the required reduction equivalents.
There are observations of decreased net glucose transport via GLUT-1 transporter
in patients with diabetes [81, 82]. Consequently, diabetic RBCs need more GLUT-1
proteins in DRM to transport the required glucose amount in addition to the
number of GLUT-1 molecules needed for rapid DHA uptake. If the increased
oxidative stress in diabetes favors the oxidation of AA to AfR and ultimately to
DHA, the required number of GLUT-1 must be greater than in healthy cells.
Figure 3.14 on page 40 shows the content of GLUT-1 in DRMs from diabetic and
healthy subjects sorted by extracellular glucose concentrations. It was observed
that diabetic RBCs 'over-react' to changes in the extracellular AA and DHA con-
centration, especially under hyperglycemic conditions, compared to healthy controls.
In summary, the results from the human study show that diabetic RBCs are able
to shuttle their GLUT-1 proteins into DRM. They regulate the GLUT-1 content
in DRM dependent on the extracellular conditions, but only in combination with
vitamin C. The decreased net glucose transport rate of GLUT-1 in diabetes [81,
82] is compensated for by increased transloction of GLUT-1 molecules into DRM.
Especially under hyperglycemic conditions, GLUT-1 is shuttled into DRM. The
result is likely improved DHA uptake and recycling of vitamin C. If this regulation
works and the eﬀect of extracellular glucose can be mediated by an increased
GLUT-1 shuttling, the uptake rate of DHA into diabetic RBCs should be equal to
that of healthy controls. Further, the transported amount of the oxidized vitamin
should be equal at any glucose concentration as long as RBCs transport suﬃcient
glucose to produce the required reduction equivalents needed for DHA recycling.
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Figure 3.14: Ratio of GLUT-1 to stomatin bands of DRM isolated from RBCs of dia-
betic (blue bars) and healthy (green bars) subjects after incubation with 3, 5 or 25mM
glucose and 100µM AA in combination with Ao to generate DHA. A statistical analysis for
signiﬁcances of the by glucose sorted data was not possible caused by the complex study
design.
Uptake kinetics of DHA showed, that there are no diﬀerences in the transport
of DHA into diabetic RBCs compared to healthy controls (ﬁg. 3.15 on page 41).
The extracellular glucose concentration had no eﬀect on the transport of DHA.
Thus, the altered GLUT-1 content found in diabetic DRM could compensate for
the decreased net transport activity of GLUT-1 proteins and no competition of
DHA with glucose was observed.
3.2.4 Ascorbate content of diabetic red blood cells in vivo
The intracellular AA concentrations of young and old RBCs from diabetic subjects
were analyzed to examine whether the ﬁndings of equal DHA transport in RBCs in
vitro can also be observed in vivo. Despite equal plasma vitamin C concentrations
(ﬁg. 5.1, page 57), diabetic RBCs show signiﬁcantly less AA in young and middle-
aged cells, the oldest RBCs of diabetic subjects also contained less intracellular
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Figure 3.15: Accumulation of AA (continous lines) and DHA (broken lines) in RBCs
obtained from healthy (left ﬁgure) and diabetic subjects (right ﬁgure). ∗ denotes signiﬁcant
diﬀerences in vitamin C treatment at the same glucose concentration and time. There are
no statistical diﬀerences between the two groups.
Figure 3.16: Intracellular AA concentration in healthy and diabetic RBCs separated by
age (n=6). ∗ denotes signiﬁcant diﬀerences for signiﬁcances of the two groups (diabetics
and controls).
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ascorbate (ﬁgure 3.16, page 41). This demonstrates, that in vivo the transport of
DHA into RBCs in diabetes mellitus is complicated. This leads to the assumption,
that diabetic subjects have a smaller AA pool in their RBCs, and, therefore, a lower
antioxidative defense compared to healthy controls. Thus, the compensation for the
eﬀect of extracellular glucose on DHA transport might be insuﬃcient. The likely
reduced DHA absorption in vivo results in decreased extracellular AA recycling by
using intracellular electrons derived from ascorbate molecules. Thus, the reference
daily intake (RDI) of vitamin C has to be reconsidered for diabetic patients to ensure
an adequate antioxidative defense.
42
3.3 Limitations
In vitro research is always associated with problems regarding the provision of the
right environment for cells and substrates. In the case of the uptake kinetic study,
the main focus is on the stability of AA and a physiologic pH of the media. Thus,
for all RBC uptake and incubation experiments phosphate buﬀered saline (PBS) has
been chosen. Of course, plasma has many more components than PBS. Possibly, the
metal ions and other micronutrients missing from PBS could inﬂuence the uptake
of DHA in vivo.
DHA uptake kinetics performed in MCDB 131 cell culture medium showed a strong
reduction in DHA uptake into RBCs compared to that performed in PBS (compare
ﬁg. 3.1, page 22 and ﬁg. 5.3, page 59). Further, in in vitro uptake kinetics, no
diﬀerences between healthy and diabetic subjects could be seen. But comparison
of intracellular AA concentration of healthy and diabetic RBCs showed signiﬁcant
diﬀerences despite equal plasma ascorbate concentrations in both groups. The cells
were analyzed immediately after blood withdrawal, thus artiﬁcial buﬀers or media
could not aﬀect the measured ascorbate concentration.
In summary, the results of this thesis provide a blueprint for how DHA transport
into RBCs is modulated. While interpreting the data, it must be considered that
biological systems are more complex and can not easily be replicated in the labora-
tory.
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Chapter 4
Conclusion
Uptake kinetics of DHA into RBCs from man, pigs, Wistar and ODS rats showed
that the classiﬁcation into species with and without ascorbate synthesis gives
no information about whether a species can transport the oxidized vitamin into
its RBCs or not. Furthermore, it was documented that there are three diﬀerent
transport types, one which can not transport DHA, one whose DHA transport
competes with the extracellular glucose, and one type in which the absorption of
the vitamin is completely unaﬀected by the extracellular glucose concentration.
There are two known GLUT isoforms, GLUT-1 and GLUT-3, that are able to
transport DHA. The altered absorption of DHA into RBC might result in the
expression of diﬀerent GLUT isoforms. Only GLUT-1 is known to translocate
into DRM, and, therefore, to interact with stomatin which is the key to glucose-
concentration-independent DHA transport. GLUT-3 can not interact with stomatin
which accounts for the competition between DHA and glucose.
Fact is that all analyzed species which lost the ability to synthesize ascorbate
express one of the DHA transporting GLUT isoforms. Consequently, the absorption
of DHA into RBCs due to the expression of a diﬀerent glucose transporter was likely
the keystone event which led to the evolutionary survival of the GLO lacking species.
Further, it was demonstrated that RBCc are not a reservoir for vitamin C
storage. The intra-erythrocyte vitamin C concentration decreases over the lifetime
of these cells. Also, RBCs do not serve as a recycling compartment which absorbs
the oxidized vitamin and disposes of the reduced form into plasma.
However, the absorption of DHA and the accumulation of ascorbate in RBCs
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increases the antioxidative capacity in blood due to the transfer of electrons from
intracellular ascorbate to extracellular AfR or DHA molecules. The beneﬁt of using
ascorbate as an electron donor might have been due to the fact that ascorbate is
much smaller than NADPH+H+ or GSH and therefore more molecules could be
stored into an erythrocyte without loosing much intracellular space and without
loosing much energy for the uptake.
In an energetic light, this recycling of plasma ascorbate is 4-6 fold more eﬀective
than the de novo synthesis of ascorbate under the assumption that vitamin C is
available in diet. This calculations are supported by documentation of the RDAs
of species, which lost the GLO. These species require less than 20% of the vitamin
C artiﬁcial GLO knock-out species need.
The expression of GLUT-1 and GLUT-3 enables a species to recycle extracellular
ascorbate by an electron transfer across the erythrocyte membrane. The evolution-
ary beneﬁt of GLUT-1 expression was the interaction with stomatin resulting in
a lack of competition between DHA and glucose for that transporter. Therefore,
DHA is more eﬀectively absorbed by RBCs and fewer molecules degrade and are
excreted int eh urine. Due to the described extracellular ascorbate recycling, all
species which express GLUT-1 in their RBCs have much smaller RDAs for vitamin
C. This results in a better antioxidant defense which is more independent on the
dietary vitamin C intake.
In diabetes mellitus type 1, lowered plasma vitamin C concentrations and de-
creased antioxidative capacities are frequently described. Analysis of GLUT-1 and
stomatin content in DRM of erythrocytes showed an altered GLUT-1 regulation in
subjects with diabetes mellitus. Signiﬁcantly more GLUT-1 molecules are translo-
cated into DRM under hyperglycemic conditions. Further, the intra-erythrocyte
vitamin C concentration is signiﬁcantly decreased.
The regulation of GLUT-1 localization into DRM is important for extracellular
ascorbate recycling by RBCs. A decreased transport of DHA leads to a decreased
number of intra-erythrocyte vitamin C molecules resulting in a decreased electron
pool which can be transferred across the membrane. This leads to lower antioxidant
defense in plasma and to an increased probability of oxidative damage. Further, a
lower absorption rate for DHA results in an increased degradation and urinary loss
of vitamin C.
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To guarantee an adequate intra-erythrocyte electron pool, which is required for
suﬃcient extracellular ascorbate recycling, the potential beneﬁt of raising the RDI
for vitamin C for diabetes patients should be investigated. A higher dietary intake
possibly improves the absorption of DHA by RBCs and supports plasma ascorbate
homeostasis.
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Chapter 5
Additional Results
5.1 Study population
Figure 5.1: Mean plasma and erythrocyte ascorbate concentration of the study population.
There were no diﬀerences in vitamin C concentrations between the two groups.
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Table 5.1: Measured parameters of the diabetic subjects and healthy controls (±
SE)
diabetic healthy
Age 32.5 ± 2.5 29.9 ± 2.5
HbA1c 7.6 ± 0.2 5.2 ± 0.2
Total cholesterin 173 ± 7 189 ± 7
CRP 0.4 ± 0.5 0.9 ± 0.2
Figure 5.2: Mean ascorbate concentrations of plasma and erythrocytes obtained from
diﬀerent species. Bars with the same letter are not signiﬁcantly diﬀerent. Capital letters
denote plasma values, small form letters denote cellular concentrations.
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5.2 DHA uptake into HMEC-1 in vitro
Figure 5.3: Uptake of DHA into HMEC-1 in media with 5mM or 25mM glucose. The
transport and intracellular accumulation is signiﬁcant less (p<0.01) in medium with high
glucose concentration, signiﬁcantly diﬀerent datapoints are denoted by ∗. The measured
AA concentration is generated by lysis of 5.5 x 106 in 300µl 5% PCA.
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5.3 Westernblots of GLUT-1, GLUT-3 and stom-
atin
Figure 5.4: Representative Westernblot of RBCs obtained from men, ODS rats, pigs ans
Wistar rats (from left to right). Samples from two individuals were analyzed, respectively.
Only human RBCs contain GLUT-1, all other species were negative.
Figure 5.5: Representative Westernblot of RBCs obtained from men, pigs, ODS rats and
Wistar rats (from left to right). Samples from two individuals were analyzed, respectively.
No GLUT-3 was found in RBCs from human and pigs. Rat RBCs showed a band at
100kDa. The molecular mass of GLUT-3 is 50-55kDa [17]. The 100kDa band belongs to a
co-localization of GLUT-3 with Hexokinase-1 like conﬁrmed by Rauch et al. [83].
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Figure 5.6: Representative Westernblot of RBCs obtained from men, ODS rats, pigs ans
Wistar rats (from left to right). Samples of two individuals were analyzes, respectively.
Rats express smaller stomatin molecules than men or pigs ( cf. Wang et al. [84]). The
double band observed in pigs belongs to a missing N-glycosylation which results in a 2-3
kDa smaller protein [85]
5.4 Graphics of transformed data with errorbars
Figure 5.7: ln-transformed data of uptake kinetics into human RBCs
61
Figure 5.8: ln-transformed data of uptake kinetics into pig RBCs
Figure 5.9: ln-transformed data of uptake kinetics into Wistar rat RBCs
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Figure 5.10: ln-transformed data of uptake kinetics into ODS rat RBCs
Figure 5.11: ln-transformed data of uptake kinetics into diabetic RBCs
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Chapter 6
Materials and Compositions
Anode buﬀer A2
300mM/L Tris Base (CarlRoth AG, Karlsruhe, Germany) with 20% methanol (Carl-
Roth AG, Karlsruhe, Germany).
Easycoll solution
Table 6.1: Manufacturing of Easycoll solution
density volume Easycoll volume PBS
1.081g/ml 6.39ml 3.91ml
1.092g/ml 7.82ml 2.18ml
1.099g/ml 7.90ml 2.10ml
Easycoll was purchased from biochrom GmbH, Berlin Germany.The solutions were
mixed at room temperature, otherwise the transferred volumes were not correct.
Sørensen buﬀer
Sørensen buﬀer is a mixture of 0.5M Na2HPO4 (Merck KGaA, Darmstadt, Germany)
solution with 0.5M NaH2PO4 (Merck KGaA, Darmstadt, Germany) solution. The
ratio of the two solutions depends on the required pH. Table 6.2shows the volume of
0.5M Na2HPO4 solution which is mixed with 0.5M NaH2PO4 solution to a volume
of 50ml resulting in a 0.5M sodium phosphate buﬀer with the required pH.
64
Table 6.2: Manufacturing of Sørensen buﬀer
pH .0 .1 .2 .3 .4 .5 .6 .7 .8 .9
5 4.9 6.0
6 7.4 9.0 10.9 13.0 15.4 18.0 20.8 23.6 26.6 29.4
7 32.2 34.8 37.2 39.2 41.1 42.7 44.0 45.2 46.0 46.7
8 47.1
Running buﬀer (Electrophorese buﬀer)
50mM/L Tris base (CarlRoth AG, Karlsruhe, Germany), 380mM Glycine (sigma-
aldrich gmbH, Munich, Germany) and 0.1% sodium dodecylsulfate (serva elec-
trophoresis GmbH, Heidelberg, Germany). The pH was adjusted to 8.5 - 8.7.
cathode buﬀer B
25mM Tris base (CarlRoth AG, Karlsruhe, Germany), 40mM aminocaproic acid
(Merck KGaA, Darmstadt, Germany) and 20% methanol (CarlRoth AG, Karlsruhe,
Germany)
Phosphate buﬀered saline (PBS)
137mM sodium chloride (Merck KGaA, Darmstadt, Germany), 2.7mM potassium
chloride (Merck KGaA, Darmstadt, Germany), 1.5mM potassium dihydrogen phos-
phate (Merck KGaA, Darmstadt, Germany) and 8mM disodium hydrogen phosphate
dihydrate (Merck KGaA, Darmstadt, Germany). The pH was adjusted to 7.4 with
hydrochloric acid.
For PBS-TX 0.5% Trinton-X100 (CarlRoth AG, Karlsruhe, Germany) was solved
at room temperature in PBS.
PBS- for cell culture
137mM sodium chloride (Merck KGaA, Darmstadt, Germany), 2.7mM potassium
chloride (Merck KGaA, Darmstadt, Germany), 1.8mM potassium dihydrogen phos-
phate (Merck KGaA, Darmstadt, Germany) and 10mM disodium hydrogen phos-
phate dihydrate (Merck KGaA, Darmstadt, Germany). The pH was adjusted to 7.4
with hydrochloric acid.
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Phosphatase and protease inhibitors
Phosphatase inhibitor stock solution was a 150mM sodium ortho vanandate solu-
tion. Aliquots were stored at -20◦C until use.
Protease inhibitor Cocktail P8340 was purchased by sigma-aldrich (Munich, Ger-
many). Aliquots were stored at -20◦C like described by the manufactorer.
4xSDS sample buﬀer
8% sodium dodecylsulfate (serva electrophoresis GmbH, Heidelberg, Germany),
0.25M Tris base (solved and adjusted to pH6.8 before)(CarlRoth AG, Karlsruhe,
Germany), 40% glycerol (CarlRoth AG, Karlsruhe, Germany), 0.003% bromphenole
blue (sigma-aldrich gmbH, Munich, Germany), 20% β-mercaptho ethanol (Merck
KGaA, Darmstadt, Germany). The volume was ﬁlled up with ultrapure Water to
10mL. Aliquots were stored at 4◦C.
colorless 1xSDS buﬀer
2% sodium dodecylsulfate (serva electrophoresis GmbH, Heidelberg, Germany),
62.5mM Tris base (solved and adjusted to pH6.8 before)(CarlRoth AG, Karlsruhe,
Germany) and 10% glycerol (CarlRoth AG, Karlsruhe, Germany). The volume was
ﬁlled up with ultrapure Water to 40ml. Aliquots were stored at room temperature.
transporter substrates
L-Ascorbic acid was purchased by CarlRoth AG (Karlsruhe, Germany). To produce
dehydroAA AA oxidase (sigma-aldrich gmbH, Munich, Germany) was added to an
AA solution like described in the manufactorers instructions. Waterfree D-glucose
was purchased from Merck (Darmstadt, Germany). Glucose stock solutions were
stored up to 4 weeks at 4◦C.
Tris buﬀeres saline with tween (TBST)
0.1M Tris base (CarlRoth AG, Karlsruhe, Germany), 0.37M sodium chloride and
0.05% Tween® 20 (serva electrophoresis GmbH, Heidelberg, Germany).
For blocking solution 5% bovine serum albumine (BSA)(CarlRoth AG, Karlsruhe,
Germany) was solved in TBST.
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